BreezeBio

BreezeBio, founded in 2021 and based in San Diego, is a private biotech advancing a novel programmable nanoparticle platform, NanoGalaxy®, for the targeted delivery of genetic medicines. The company is initially focused on restoring immune balance in autoimmune diseases, with a lead program (BRZ-101) in Type 1 Diabetes and a broader pipeline in autoimmunity and oncology. BreezeBio has secured significant venture financing and established key partnerships with Genentech and Sarepta Therapeutics, positioning it as a promising player in the next generation of genetic medicine delivery.

NanoGalaxy®: A programmable library of non-immunogenic nanoparticles designed for targeted delivery of genetic payloads (e.g., mRNA) to specific cells, particularly antigen-presenting cells (APCs), to induce antigen-specific immune tolerance or other therapeutic effects.

BreezeBio competes with other biotechs developing targeted non-viral delivery (e.g., Vesigen Therapeutics, ReCode Therapeutics) and tolerance-inducing therapies for autoimmunity (e.g., Anokion, Cour Pharmaceuticals). It also competes indirectly with large pharma and biotech companies advancing RNA/gene therapies with their own delivery technologies.